Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 5/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 1/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122271 | 0.92 | PDE5A (0.47) | MEN1KMT2APRKCIABCB1ABCG2 | |
| SCHEMBL5130261 | 0.89 | MEN1 (0.52) | MEN1KMT2AABCB1ABCG2USP1 | |
| SCHEMBL8180396 | 0.87 | MEN1 (0.52) | MEN1KMT2ABCHEACHEAPP | |
| SCHEMBL8169994 | 0.87 | MEN1 (0.50) | MEN1KMT2ABCHEACHEAPP | |
| SCHEMBL5125267 | 0.87 | PRKCI (0.62) | MEN1KMT2APRKCIBCHEACHE | |
| SCHEMBL5120390 | 0.86 | MEN1 (0.57) | MEN1KMT2APRKCIBCHEACHE | |
| SCHEMBL5123250 | 0.85 | MEN1 (0.43) | MEN1KMT2ABCHEACHEAPP | |
| SCHEMBL5128675 | 0.85 | MEN1 (0.56) | MEN1KMT2APRKCIBCHEACHE | |
| SCHEMBL5122390 | 0.85 | MEN1 (0.45) | MEN1KMT2ABCHEACHEAPP | |
| SCHEMBL5115713 | 0.85 | PRKCI (0.48) | MEN1KMT2APRKCIUSP1WDR48 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | MEN1 696/4885KMT2A 388/4885PRKCI 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.